FibroGen (FGEN) Misses Q1 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to FibroGen (FGEN) Misses Q1 EPS by 26c

FibroGen Announces First Quarter 2015 Financial Results

May 12, 2015 7:02 AM EDT

SAN FRANCISCO--(BUSINESS WIRE)-- FibroGen, Inc. (NASDAQ: FGEN) (FibroGen), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015.

FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease, said Thomas B. Neff, chief executive officer of FibroGen. Patient enrollment in the seven Phase 3 studies required for approval in the U.S. and Europe is advancing as planned. In China, we expect to begin patient enrollment in both Phase 3 studies required for... More